Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer

Kazuhiro Araki, Yasuo Miyoshi


Clinical oncology has progressed in elucidating multiple aspects for cancer chemotherapy. For most malignancies, we now face many therapeutic options to discuss with patients with cancer. Optimal chemotherapy-sparing regimens are preferable for patients with breast cancer.